ARTBIO Announces Appointment of Margaret Yu, M.D., as Chief Medical Officer

CAMBRIDGE, Mass.; OSLO, Norway – January 9, 2025 — ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), announces the appointment of Margaret Yu, M.D., as Chief Medical Officer. Dr. Yu joins ARTBIO with more than 15 years of oncology drug development experience. In this role, Dr. Yu will spearhead clinical development and regulatory strategies to drive the advancement and delivery of innovative ARTs to patients in need.

"We are delighted to welcome Margaret to our leadership team. Her extensive experience in oncology drug development, strategic leadership in clinical programs, and proven ability to deliver high-quality outcomes make her an outstanding fit for our organization,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO. “Margaret will play a pivotal role in advancing the development of our alpha radioligand therapies based on the ideal Pb212 isotope, overseeing clinical development, regulatory strategy, and medical affairs to ensure the successful progression of our pipeline.”

Margaret Yu joins ARTBIO from her former role as Vice President, Integration and Asset Externalization Lead at Johnson & Johnson. Prior to that, she had an extensive career at Janssen, where she served as Clinical Leader for the ZYTIGA and ERLEADA programs, successfully building and managing the ERLEADA clinical development program and leading the team to the first regulatory submission in non-metastatic castration-resistant prostate cancer. She also played a key role in clinical strategy for niraparib and served as Prostate Disease Area Stronghold Leader, where she advanced Janssen’s prostate cancer pipeline, including biologics now in late clinical development. Margaret began her career in the pharmaceutical industry as Director of Clinical Research at Myriad Pharmaceuticals, Inc., and later transitioned into oncology drug development roles at Janssen, where she built strong relationships with external stakeholders and advanced key clinical milestones. Margaret is a medical oncologist who completed her residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the University of Utah. She is also an active member of the American Society of Clinical Oncology and has authored numerous publications in the field.

"I am thrilled to join the impressive team at ARTBIO,” said Margaret Yu, M.D. "The growing enthusiasm surrounding radiopharmaceuticals and their impact in the biotech industry has soared in recent years, with ARTBIO’s unique approach and proprietary AlphaDirectTM technology presenting numerous opportunities to benefit cancer patients. Alpha radioligand therapy represents a novel class of cancer treatment, and I look forward to contributing to ARTBIO’s growth trajectory.”

About ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (²¹²Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind ²¹²Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first-in-human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter.